The agency will review Mylan and Biocon’s biosimilar to pegfilgrastim.
On July 21, 2016 Mylan and Biocon announced that the European Medicines Agency (EMA) has accepted for review Mylan’s Marketing Authorization Application (MAA) for its proposed biosimilar to pegfilgrastim. The drug was co-developed by Biocon and Mylan and is used to treat cancer patients. The drug minimizes the side effects of chemotherapy treatment, reducing the duration of neutropenia. According to Mylan, in addition to analytical, functional, and preclinical data, the application includes clinical data from pharmacokinetic/pharmacodynamic (PK/PD) studies completed earlier in 2016.
This comes after FDA sent a complete response letter to Sandoz for Neulasta, its biosimilar candidate to pegfilgrastim. Novartis released a statement in its Q2 report saying the company is working with FDA to address remaining questions.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.